Month: March 2022

CALGARY, Alberta, March 14, 2022 (GLOBE NEWSWIRE) — Petrus Resources Ltd. (“Petrus” or the “Company“) (TSX: PRQ) is pleased to announce that it has closed its previously announced acquisition of a privately owned limited partnership and its general partner for total consideration of approximately $14.4 million, consisting of the issuance of 10 million common shares of the Company. Petrus’ approved 2022 capital budget remains at $50-$55 million following the acquisition. Capital will be largely focused on the drilling, completion and tie-in of 14 net wells in Ferrier. The 2022 budget was constructed using a price forecast of WTI at US$69.00/bbl, AECO at $3.20/GJ and a foreign exchange rate of US$0.79. Through the successful execution of this capital plan and with the acquired entities now included, Petrus...

Imsidolimab (anti-IL-36R Ab) treatment did not demonstrate improvement over placebo in top-line primary or secondary endpoints AnaptysBio to discontinue imsidolimab clinical development in acne Imsidolimab was generally safe, well tolerated and no imsidolimab-related serious or severe adverse events were reported Enrollment ongoing in imsidolimab GEMINI-1 GPP Phase 3 trial and top-line data from HARP Phase 2 trial in moderate-to-severe hidradenitis suppurativa anticipated in H2 2022 Rosnilimab (anti-PD-1 agonist Ab) AZURE Phase 2 moderate-to-severe alopecia areata enrollment ongoing and ANB032 (anti-BTLA modulator Ab) Phase 1 healthy volunteer top-line data anticipated in Q2 2022 Continue to operate in a capital-efficient manner with approximately $615 million in cash at end 2021 and anticipated 2022 net cash burn of $90 to $100 millionSAN...